National and Kapodistrian University of Athens
Συμμετοχή του αποπτωτικού μονοπατιού TRAIL στην καρκινογένεση
Abstract
dc:descriptionIntroduction: Regulated apoptosis is vital for the development and homeostasis and is commonly deregulated during human carcinogenesis. TNF-related, apoptosis-inducing ligand (TRAIL) apoptotic pathway constitutes a promising therapeutic target due to high selectivity and low toxicity of TRAIL targeting agents when administered in combination therapies. TRAIL extrinsic apoptotic pathway consists of the TNF Related Apoptosis Inducing Ligand which can bind on two apoptosis inducing receptors (DR4, DR5), two decoy receptors incapable of transmitting an apoptotic signal (DcR1, DcR2) and a soluble decoy receptor osteoprotegerin (OPG). Inhibitors of TRAIL induced apoptosis include several genes, such as: c-FLIP, XIAP, Mcl-1, Bcl-2 and Bcl-xL. In detail, c-FLIP inhibits DISC formation, Bcl2, Bcl-xL, Mcl-1 inhibit the proapoptotic Bcl-2 family members Bax and Bak, and finally XIAP pre-vents Caspase-3 activation.Materials and Methods: 106 colorectal cancers were examined for relative mRNA expression of genes involved in TRAIL pathway function and regulation (TRAIL, DR4, DR5, DcR1, DcR2, Bcl2, Bcl-XL, Mcl-1, c-FLIP and XIAP) with ΔΔCt analysis. Furthermore, 53 samples were analyzed for mutations in MAPK/ERK genes KRAS (Exons 2,3 and 4), NRAS (Exons 2,3 and 4) and BRAF (exon 15) with Real Time HRM PCR. 44 samples were also analyzed with MS-PCR for decoy receptor (DCR1 and DCR2) promoter methylation in order to assess decoy receptor methylation as a possible expression-reducing mechanism. Additionally, MSI analysis was performed with Real Time HRM-PCR in order to properly assess grading to 14 mucinous adenocarcinomas (according to W.H.O.).Results: Elevated mRNA levels were observed in 66%, 50%, 45%, 33%, 29%, 26%, 15%, 13%, 12% and 10% of the cases for c-FLIP, Bcl-XL, Mcl-1, Bcl2, XIAP, DCR2, DCR1, DR5, DR4 and TRAIL genes respectively. Reduced mRNA levels were detected in 77%, 65%, 64%, 60%, 37%, 33%, 21%, 26%, 20% and 20% of the cases for TRAIL, DR5, DCR1, DR4, DCR2, Bcl2, Bcl-XL Mcl-1 c-FLIP and XIAP genes respectively. Unchanged mRNA levels were detected in 55%, 38%, 34%, 29%, 29%, 28%, 22%, 21%, 14% and 13% of the cases for XIAP DcR2 Bcl2 Bcl-XL Mcl-1 DR4 DR5 DcR1 c-FLIP and TRAIL genes respec-tively. DCR1 and DCR2 promoter methylation was detected in 55% and 16% of the analyzed samples respectively. Mutations in MAPK/ERK pathway genes were detected in 57% of the samples analyzed of which: 45% of the samples were mutated in KRAS, 6% in NRAS and 6% in BRAF. Statistically significant correlations were found between: between DR4 and DR5 elevated relative mRNA expression and tumor stage (inversely, p=0.036, p=0.048 respectively), be-tween XIAP and Mcl-1 elevated relative mRNA expression and T (positively, p=0,059; in-versely, p=0,052), Bcl2 reduced relative mRNA expression and grade, G (positively, p=0,049), c-FLIP and DR5 unchanged relative mRNA expression and gender (with men, p=0,036 and p=0,078 respectively). Strong positive linear correlations mRNA levels were found: c-FLIP/Bcl-XL (p<0,001 και Rs=0,904), c-FLIP/Mcl-1 (p<0,001 και Rs=0,729), DR4/DR5 (R=0.653, p<0.001), XIAP/Mcl-1 (p<0,001 και Rs=0,648) and Mcl-1/Bcl-XL (p<0,001 και R=0,692). .Finally, relative expression of TRAIL was correlated with KRAS, BRAF and NRAS mutation status, defining an inverse correlation between increased TRAIL expression and the absence of mutations in Mitogen-activated protein kinase (MAPK) path-way , and inverse correlations between XIAP reduced mRNA expression and KRAS/NRAS mutations. Conclusions: Simultaneous analysis of TRAIL pathway membrane components, pointed towards a significant deregulation of mRNA expression in colorectal tumours. Multiple expression patterns of TRAIL pathway components in colorectal tumours emerged in the current study, which may possibly be of future use as predictive biomarkers for proper patient selection in order to achieve maximum efficiency with TRAIL targeted therapy in colorectal cancer clinical practice. Further validation of these results in larger patient cohorts is required, as well as further research regarding interactions with other signaling pathways involved in carcinogenesis.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsikalakis, Spyridon
- Τσικαλάκης, Σπυρίδων
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43330